Skip to main content

Advertisement

SpringerLink
Log in

Matrix metalloproteinase 2 polymorphisms and expression in lung cancer: a meta-analysis

  • Research Article
  • Published:
Tumor Biology

Abstract

A number of studies have investigated the role of matrix metalloproteinase 2 (MMP2) polymorphisms and expression in lung cancer, but have yielded inconsistent and inconclusive results. To derive a more precise estimate of the prognostic role of MMP2 expression and the susceptibility role of MMP2 polymorphisms in lung cancer, we reviewed published studies and carried out a meta-analysis. Eligible articles were identified in electronic databases. Case–control studies assessing the associations between MMP2 polymorphisms and lung cancer risk or cohort studies assessing the prognostic role of MMP2 expression in patients with lung cancer were included. Pooled odds ratio (OR) or hazard ratio (HR) with 95 % confidence interval (95 % CI) was used to assess the role of MMP2 polymorphisms and expression in lung cancer, respectively. Seven case–control studies (a total of 3,190 lung cancer cases and 3,013 controls) and 18 cohort studies (2,095 lung cancer patients) were eligible. Meta-analysis of seven case–control studies suggested that individuals with TT genotype of both MMP2 C735T and C1306T polymorphisms had obviously decreased risk of lung cancer compared with those with CC genotype (for MMP2 C735T, fixed effects OR = 0.69, 95 % CI 0.49–0.97, P = 0.032; for MMP2 C1306T, fixed effects OR = 0.54, 95 % CI 0.33–0.86, P = 0.010). Meta-analysis of 18 cohort studies suggested that patients with high MMP-2 expression had poorer overall survival (fixed effects HR = 1.82, 95 % CI 1.56–2.13, P < 0.001). Subgroup by study design, ethnicity and testing methods all further identified the prognostic value of MMP2 expression in lung cancer. In conclusion, MMP2 C735T and C1306T polymorphisms are both associated with lung cancer risk, and patients with high MMP2 expression levels have poorer overall survival compared with those with low MMP2 expression levels.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2
Fig. 3
Fig. 4

Similar content being viewed by others

References

  1. Herbst RS, Heymach JV, Lippman SM. Lung cancer. N Engl J Med. 2008;359:1367–80.

    Article  PubMed  CAS  Google Scholar 

  2. Goldstraw P, Ball D, Jett JR, Le Chevalier T, Lim E, Nicholson AG, Shepherd FA. Non-small-cell lung cancer. Lancet. 2011;378:1727–40.

    Article  PubMed  Google Scholar 

  3. Spira A, Ettinger DS. Multidisciplinary management of lung cancer. N Engl J Med. 2004;350:379–92.

    Article  PubMed  CAS  Google Scholar 

  4. Nelson AR, Fingleton B, Rothenberg ML, Matrisian LM. Matrix metalloproteinases: biologic activity and clinical implications. J Clin Oncol. 2000;18:1135–49.

    PubMed  CAS  Google Scholar 

  5. Egeblad M, Werb Z. New functions for the matrix metalloproteinases in cancer progression. Nat Rev Cancer. 2002;2:161–74.

    Article  PubMed  CAS  Google Scholar 

  6. Ye S. Polymorphism in matrix metalloproteinase gene promoters: implication in regulation of gene expression and susceptibility of various diseases. Matrix Biol. 2000;19:623.

    Article  PubMed  CAS  Google Scholar 

  7. Price S, Greaves D, Watkins H. Identification of novel, functional genetic variants in the human matrix metalloproteinase-2 gene: role of Sp1 in allele-specific transcriptional regulation. J Biol Chem. 2001;276:7549.

    Article  PubMed  CAS  Google Scholar 

  8. Aysegul B, Veysi GH, Muzaffer M, Irfan D, Azra A, Hulyam K. Is a single nucleotide polymorphism a risk factor for lung cancer in the matrix metalloproteinase-2 promoter? Mol Biol Rep. 2011;38:1469–74.

    Article  PubMed  Google Scholar 

  9. Rollin J, Regina S, Vourc'h P, Iochmann S, Blechet C, Reverdiau P, Gruel Y. Influence of MMP-2 and MMP-9 promoter polymorphisms on gene expression and clinical outcome of non-small cell lung cancer. Lung Cancer. 2007;56:273–80.

    Article  PubMed  Google Scholar 

  10. Yu C, Pan K, Xing D, Liang G, Tan W, Zhang L, Lin D. Correlation between a single nucleotide polymorphism in the matrix metalloproteinase-2 promoter and risk of lung cancer. Cancer Res. 2002;62:6430–3.

    PubMed  CAS  Google Scholar 

  11. Gonzalez-Arriaga P, Pascual T, Garcia-Alvarez A, Fernandez-Somoano A, Lopez-Cima MF, Tardon A. Genetic polymorphisms in MMP 2, 9 and 3 genes modify lung cancer risk and survival. BMC Cancer. 2012;12:121.

    Article  PubMed  CAS  Google Scholar 

  12. Cox G, Jones JL, Andi A, Waller DA, O'Byrne KJ. A biological staging model for operable non-small cell lung cancer. Thorax. 2001;56:561–6.

    Article  PubMed  CAS  Google Scholar 

  13. Matsuo Y, Hashimoto S, Koga T, Yonemitsu Y, Yoshino I, Sugimachi K, Honda H, Masuda K, Sueishi K. Growth pattern correlates with the distribution of basement membrane and prognosis in lung adenocarcinoma. Pathol Res Pract. 2004;200:517–29.

    Article  PubMed  Google Scholar 

  14. Kodate M, Kasai T, Hashimoto H, Yasumoto K, Iwata Y, Manabe H. Expression of matrix metalloproteinase (gelatinase) in T1 adenocarcinoma of the lung. Pathol Int. 1997;47:461–9.

    Article  PubMed  CAS  Google Scholar 

  15. Yamamura T, Nakanishi K, Hiroi S, Kumaki F, Sato H, Aida S, Kawai T. Expression of membrane-type-1-matrix metalloproteinase and metalloproteinase-2 in nonsmall cell lung carcinomas. Lung Cancer. 2002;35:249–55.

    Article  PubMed  Google Scholar 

  16. Shou YN, Ping YL, Gong YB, Jia TJ, Ji QH, Dai PD, Chi QJ, Liu DN, Jia TZ. The expression of vegf and MMP-2 in non-small cell lung cancer and their association with pathological factors and prognosis. J China-Japan Friendship Hosp. 2004;8:275–7 [Article in Chinese].

    Google Scholar 

  17. Grossi F, Spizzo R, Bordo D, Cacitti V, Valent F, Rossetto C, Follador A, Di Terlizzi S, Aita M, Morelli A, Fasola G, Consiglieri C, Ceschia T, Beltrami CA, Belvedere O. Prognostic stratification of stage IIIA pN2 non-small cell lung cancer by hierarchical clustering analysis of tissue microarray immunostaining data: an Alpe Adria Thoracic Oncology Multidisciplinary Group study (ATOM 014). J Thorac Oncol. 2010;5:1354–60.

    Article  PubMed  Google Scholar 

  18. Passlick B, Sienel W, Seen-Hibler R, Wockel W, Thetter O, Mutschler W, Pantel K. Overexpression of matrix metalloproteinase 2 predicts unfavorable outcome in early-stage non-small cell lung cancer. Clin Cancer Res. 2000;6:3944–8.

    PubMed  CAS  Google Scholar 

  19. Ishikawa S, Takenaka K, Yanagihara K, Miyahara R, Kawano Y, Otake Y, Hasegawa S, Wada H, Tanaka F. Matrix metalloproteinase-2 status in stromal fibroblasts, not in tumor cells, is a significant prognostic factor in non-small-cell lung cancer. Clin Cancer Res. 2004;10:6579–85.

    Article  PubMed  CAS  Google Scholar 

  20. Shou Y, Hirano T, Gong Y, Kato Y, Yoshida K, Ohira T, Ikeda N, Konaka C, Ebihara Y, Zhao F, Kato H. Influence of angiogenetic factors and matrix metalloproteinases upon tumour progression in non-small-cell lung cancer. Br J Cancer. 2001;85:1706–12.

    Article  PubMed  CAS  Google Scholar 

  21. Parmar MK, Torri V, Stewart L. Extracting summary statistics to perform meta-analyses of the published literature for survival endpoints. Stat Med. 1998;17:2815–34.

    Article  PubMed  CAS  Google Scholar 

  22. Higgins JP, Thompson SG, Deeks JJ, Altman DG. Measuring inconsistency in meta-analyses. BMJ. 2003;327:557–60.

    Article  PubMed  Google Scholar 

  23. Cochran WG. The combination of estimates from different experiments. Biometrics. 1954;10:101–29.

    Article  Google Scholar 

  24. DerSimonian R, Laird N. Meta-analysis in clinical trials. Control Clin Trials. 1986;7:177–88.

    Article  PubMed  CAS  Google Scholar 

  25. Mantel N, Haenszel W. Statistical aspects of the analysis of data from retrospective studies of disease. J Natl Cancer Inst. 1959;22:719–48.

    PubMed  CAS  Google Scholar 

  26. Stuck AE, Rubenstein LZ, Wieland D. Bias in meta-analysis detected by a simple, graphical test. Asymmetry detected in funnel plot was probably due to true heterogeneity. BMJ. 1998;316:469.

    Article  PubMed  CAS  Google Scholar 

  27. Egger M, Davey Smith G, Schneider M, Minder C. Bias in meta-analysis detected by a simple, graphical test. BMJ. 1997;315:629–34.

    Article  PubMed  CAS  Google Scholar 

  28. Jia SX, Ding CM. Association of single nucleotide polymorphisms in the promoter of MMP-2 and TIMP-2 genes with lung cancer. Wanfang Master Thesis Database. 2009. [Article in Chinese].

  29. Song XY, Li L, Zhang L, Xiong X. Association polymorphisms in the matrix metalloproteinases-2 (MMP-2) gene with non-small cell lung cancer. Sichuan Zhong Liu Fang Zhi. 2007;20:257–9 [Article in Chinese].

    Google Scholar 

  30. Zhou Y, Yu C, Miao X, Wang Y, Tan W, Sun T, Zhang X, Xiong P, Lin D. Functional haplotypes in the promoter of matrix metalloproteinase-2 and lung cancer susceptibility. Carcinogenesis. 2005;26:1117–21.

    Article  PubMed  CAS  Google Scholar 

  31. Wang S, Li B, Li Y, Li J. Expression and clinical significance of CD147 and MMP-2 in squamous cell carcinoma and adenocarcinoma of the lungs. Zhongguo Fei Ai Za Zhi. 2011;14:710–4 [Article in Chinese].

    PubMed  Google Scholar 

  32. Zhang HZ, Wei YP, Li HG, Wang M, Liu JG, Wu C. Expressions of vascular endothelial growth factor C and matrix metalloproteinases-2 and prognosis of non-small cell lung carcinoma. Nan Fang Yi Ke Da Xue Xue Bao. 2006;26:1307–10 [Article in Chinese].

    PubMed  CAS  Google Scholar 

  33. Byun JH, Lee MA, Roh SY, Shim BY, Hong SH, Ko YH, Ko SJ, Woo IS, Kang JH, Hong YS, Lee KS, Lee AW, Park GS, Lee KY. Association between cyclooxygenase-2 and matrix metalloproteinase-2 expression in non-small cell lung cancer. Jpn J Clin Oncol. 2006;36:263–8.

    Article  PubMed  Google Scholar 

  34. Shao W, Wang W, Xiong XG, Cao C, Yan TD, Chen G, Chen H, Yin W, Liu J, Gu Y, Mo M, He J. Prognostic impact of MMP-2 and MMP-9 expression in pathologic stage ia non-small cell lung cancer. J Surg Oncol. 2011;104:841–6.

    Article  PubMed  CAS  Google Scholar 

  35. Xue Y, Zhou QH, Zhang SF, Liu LX. A study on the relationship between expression of MMP-2, MMP-9 and metastasis and prognosis in patients with lung cancer. Hua Xi Yi Xue. 2008;23:225–8 [Article in Chinese].

    CAS  Google Scholar 

  36. Leinonen T, Pirinen R, Bohm J, Johansson R, Kosma VM. Increased expression of matrix metalloproteinase-2 (MMP-2) predicts tumour recurrence and unfavourable outcome in non-small cell lung cancer. Histol Histopathol. 2008;23:693–700.

    PubMed  Google Scholar 

  37. Hoikkala S, Paakko P, Soini Y, Makitaro R, Kinnula V, Turpeenniemi-Hujanen T. Tissue MMP-2 and MMP-9 [corrected] are better prognostic factors than serum MMP-2/TIMP-2—complex or TIMP-1 [corrected] in stage [corrected] I–III lung carcinoma. Cancer Lett. 2006;236:125–32.

    Article  PubMed  CAS  Google Scholar 

  38. Zhang HZ, Lu ZQ, Xie DR, Li HG, Xiong LH, Zhang H, Chen XB. Effect of cyclooxygenase-2, and matrix metalloproteinase-2 expression on prognosis of lung cancer. Ai Zheng. 2004;23:1190–3 [Article in Chinese].

    PubMed  CAS  Google Scholar 

  39. Wong XW, Ren Z, Zhang JH, Liang CZ. Interstitial fibroblasts and tumor cell matrix metalloproteinase-2 expression in non-small cell lung cancer and clinical significance. Shiyong Yi Xue Za Zhi. 2009;25:235-37.

    Google Scholar 

  40. Malats N, Bustos A, Nascimento CM, Fernandez F, Rivas M, Puente D, Kogevinas M, Real FX. P53 as a prognostic marker for bladder cancer: a meta-analysis and review. Lancet Oncol. 2005;6:678–86.

    Article  PubMed  CAS  Google Scholar 

  41. Popat S, Matakidou A, Houlston RS. Thymidylate synthase expression and prognosis in colorectal cancer: a systematic review and meta-analysis. J Clin Oncol. 2004;22:529–36.

    Article  PubMed  CAS  Google Scholar 

  42. Zintzaras E, Lau J. Synthesis of genetic association studies for pertinent gene-disease associations requires appropriate methodological and statistical approaches. J Clin Epidemiol. 2008;61:634–45.

    Article  PubMed  Google Scholar 

  43. Bonomi P. Matrix metalloproteinases and matrix metalloproteinase inhibitors in lung cancer. Semin Oncol. 2002;29:78–86.

    Article  PubMed  CAS  Google Scholar 

  44. Chetty C, Rao JS, Lakka SS. Matrix metalloproteinase pharmacogenomics in non-small-cell lung carcinoma. Pharmacogenomics. 2011;12:535–46.

    Article  PubMed  CAS  Google Scholar 

  45. McColgan P, Sharma P. Polymorphisms of matrix metalloproteinases 1, 2, 3 and 9 and susceptibility to lung, breast and colorectal cancer in over 30,000 subjects. Int J Cancer. 2009;125:1473–8.

    Article  PubMed  CAS  Google Scholar 

  46. Qian Q, Wang Q, Zhan P, Peng L, Wei SZ, Shi Y, Song Y. The role of matrix metalloproteinase 2 on the survival of patients with non-small cell lung cancer: a systematic review with meta-analysis. Cancer Invest. 2010;28:661–9.

    Article  PubMed  Google Scholar 

Download references

Acknowledgments

We thank professor Li in the Department of Statistics of Tongji University for his kind statistical help.

Conflicts of interest

None.

Author information

Authors and Affiliations

  1. Department of Oncology, Shanghai Pulmonary Hospital, Tongji University School of Medicine, Shanghai, 200433, China

    Jiying Wang

  2. Department of Radiation Oncology, Shanghai Pulmonary Hospital, Tongji University School of Medicine, No. 507 Zhengmin Road, Shanghai, 200433, China

    Yong Cai

Authors
  1. Jiying Wang
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Yong Cai
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Yong Cai.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Wang, J., Cai, Y. Matrix metalloproteinase 2 polymorphisms and expression in lung cancer: a meta-analysis. Tumor Biol. 33, 1819–1828 (2012). https://doi.org/10.1007/s13277-012-0441-0

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s13277-012-0441-0

Keywords

Search

Navigation